



## **Iovance Biotherapeutics to Host Conference Call to Discuss Third Quarter 2017 Financial Results and Provide a Corporate Update on Tuesday, October 31, 2017**

October 25, 2017

SAN CARLOS, Calif., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its third quarter 2017 financial and operating results after the close of the U.S. financial markets on Tuesday, October 31, 2017. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.

In order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 1423064. The live webcast can be accessed under "News & Events" in the "Investors" section of the Company's website at <http://www.iovance.com/> or you may use the link: <https://edge.media-server.com/m6/p/q7762k6j>.

A replay of the call will be available from October 31, 2017 at 7:00 p.m. ET to November 30, 2017 at 8:30 p.m. ET. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 1423064. The archived webcast will be available for thirty days in the Investors section of Iovance Biotherapeutics' website at <http://www.iovance.com/>.

### **About Iovance Biotherapeutics, Inc.**

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer. For more information, please visit <http://www.iovance.com>.

### **Investor Contact:**

Sarah McCabe  
Stern Investor Relations, Inc.  
212-362-1200  
[sarah@sternir.com](mailto:sarah@sternir.com)

### **Media Contact:**

Evan Smith/Kotaro Yoshida  
FTI Consulting  
212-850-5622/212-850-5690  
[evan.smith@fticonsulting.com](mailto:evan.smith@fticonsulting.com)  
[kotaro.yoshida@fticonsulting.com](mailto:kotaro.yoshida@fticonsulting.com)



Iovance Biotherapeutics, Inc.